YPSOMED HOLDING AG ISIN: CH0019396990 WKN: 1939699



Asset Class: Stock

Company Profile

Ypsomed Holding AG engages in the development and manufacture of injection systems for self-medication of drugs by patients, most notably used to treat diabetes. It operates through the following segments: Ypsomed Diabetes Care, Ypsomed Delivery Systems, and Others. The Ypsomed Diabetes Care segment is involved in the products that are sold directly to hospitals, doctors, pharmacies, and patients via Ypsomed subsidiaries and distributors. The Ypsomed Delivery Systems segment focuses on the pharmaceutical and biotech customers with injection systems and related services. The Others segment consists of Ypsotec and properties not used for operational purposes. The company was founded by Wilhelm Michel on December 29, 2003 and is headquartered in Burgdorf, Switzerland.

Financial figures, Fiscal year: from 01.04. to 31.03.

	20	24	20	22	20	2 2
Financial figures		Liabilities and equity		Liabilities and equity		Liabilities and equity
Current assets	337,945,000		208,327,000		193,584,000	
Common stock capital		193,144,000		193,144,000		178,994,000
Fixed assets	763,450,000		653,552,000		563,326,000	
Equity capital of a company		617,736,000		562,333,000		392,540,000
Cash and cash equivalents	73,442,000		24,477,000		15,859,000	
Accrued liabilities		8,181,000		9,839,000		6,512,000
Other assets	-		-		-	
Current liabilities		440,223,000		258,988,000		237,336,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		35,707,000		32,582,000		119,295,000
Different income		-		-		-
Other liabilities		24,306,000		20,233,000		0
Total assets	1,101,395,000	1,101,395,000	861,879,000	861,879,000	756,910,000	756,910,000

Balance notes

	2024	2023	2022
Accounting standard	-	-	-
Employees	2,296	1,978	1,831
Equity ratio	56.09%	65.25%	51.86%
Debt-equity ratio	78.30%	53.27%	92.82%

Others			
	2024	2023	2022
Tax Expense Rate	4.28%	9.47%	9.53%

YPSOMED HOLDING AG

ISIN: CH0019396990 WKN: 193	9699 Asset Class: Stock
-----------------------------	-------------------------

Income statement

	2024	2023	2022
Turnover	548,457,000	497,460,000	464,841,000
Net income	78,366,000	51,275,000	23,105,000
EBIT	89,148,410	60,550,302	28,562,142
Operating income before taxes	81,872,000	56,637,000	25,540,000
Cash Flow	163,224,000	129,531,000	85,706,000
Net interest income	-4,882,000	-2,287,000	-2,255,000
Research and development expenses	-	-	-
Income taxes	3,506,000	5,362,000	2,435,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	245,468	258,438	260,880

Board of Directors

Martin C. Münchbach	Member of the administrative board
Betül Susamis Unaran	Member of the administrative board
Paul R. Fonteyne	Member of the administrative board
Gilbert Achermann	Chairman of the administrative boar

Members of Management Board

Simon Michel	Chairman of Managing Board
Frank Mengis	Member of Executive Committee
Michael Zaugg	Member of Executive Committee
Niklaus Ramseier	Member of Executive Committee
Sébastien Delarive	Member of Executive Committee
Ulrike Bauer	Member of Executive Committee